Citations

Clear

1432 citation(s) found for "Uk, Nathan".

High fat diet and exercise lead to a disrupted and pathogenic DNA methylome in mouse liver
Zhou, Dan , Hlady, Ryan A. , Schafer, Marissa , White, Thomas A. , Liu, Chen , Choi, Jeong‐Hyeon , Miller, Jordan D. , Roberts, Lewis R. , LeBrasseur, Nathan K. , Robertson, Keith D. , Schafer, Marissa J, Roberts, Lewis R , Robertson, Keith D , LeBrasseur, Nathan K , Schafer, Marissa J , Liu, Chen , Miller, Jordan

Mayo Clinic

Epigenetics | November 18, 2016 | Volume: 12 | Issue: 1 | Pages: 55-69

10.1080/15592294.2016.1261239 | PMID 27858497 Get It

Meal replacements followed by topiramate for the treatment of adolescent severe obesity: A pilot randomized controlled trial
Kaizer, Alexander , Rudser, Kyle , Nathan, Brandon M. , Gross, Amy C. , Sunni, Muna , Abuzzahab, M. Jennifer, Schwartz, Betsy L., Kumar, Seema , Petryk, Anna , Ryder, Justin R. , Kelly, Aaron S. , Fox, Claudia K. , Billington, Charles J. , Fox, C K , Ryder, J R , Kaizer, Alexander M , Kelly, Aaron S

Mayo Clinic

Obesity | November 3, 2016 | Volume: 24 | Issue: 12 | Pages: 2553-2561

10.1002/oby.21633 | PMID 27807925 Get It

ObjectiveTo assess the safety and efficacy of short‐term meal replacement therapy followed by topiramate for body mass index (BMI) reduction in adolescents with severe obesity.MethodsAdolescents (ages 12–18 years) with severe obesity (BMI ≥1.2 times the 95th percentile or BMI ≥35 kg/m2) were recruited for this double‐blind, randomized, placebo‐controlled trial. Participants completed 4 weeks of meal replacement therapy followed by randomization (1:1) to either 24 weeks of topiramate 75 mg/day or placebo. Mean changes were compared between groups.ResultsThirty adolescents (mean age 15.2 ± 1.7 years, mean BMI 40.3 ± 4.6 kg/m2) completed the meal replacement phase and were randomized; 21 completed the study. The difference in mean percent change in BMI between the topiramate and placebo groups was not significant (−1.9%; 95% CI: −5.2% to +1.5%; P = 0.291). Significant improvements in visceral fat and very‐low‐density lipoprotein cholesterol were observed in the topiramate compared with the placebo group. There were no concerning changes in neurocognitive function or bone health.ConclusionsIn this pilot study, 4 weeks of meal replacement therapy followed by 24 weeks of low‐dose topiramate compared with meal replacement therapy alone did not result in significant BMI reduction for adolescents with severe obesity.
Safety of intrathecal autologous adipose-derived mesenchymal stromal cells in patients with ALS
Staff, Nathan P. , Madigan, Nicolas N. , Jentoft, Mark E. , Sorenson, Eric J. , Butler, Greg W., Gastineau, Dennis A., Dietz, Allan B. , Windebank, Anthony J. , Jentoft, Mark, Butler, Greg, Gastineau, Dennis, Dietz, Allan, Morris, Jonathan M. , Gastineau, Dennis A. , Staff, Nathan P , Dietz, Allan B

Mayo Clinic

Neurology | October 26, 2016 | Volume: 87 | Issue: 21 | Pages: 2230-2234

10.1212/wnl.0000000000003359 | PMID 27784774 Get It

O2‐10‐04: A Regulatory Variant at the TREM Gene Cluster Associates with Decreased Alzheimer’s Disease Risk and Increased TREML1 and TREM2 Brain Gene Expression
Carrasquillo, Minerva M. , Allen, Mariet , Strickland, Samantha L. , Aryal, Shivani , Kachadoorian, Michaela, Medway, Christopher, Younkin, Curtis, Nair, Asha, Chanana, Pritha , Wang, Xue , Serie, Daniel, Nguyen, Thuy , Lincoln, Sarah, Malphrus, Kimberly G., Golde, Todd E. , Jager, Philip L. De , Asmann, Yan W. , Younkin, Steven G., Ertekin‐Taner, Nilüfer , Carrasquillo, Minerva M. , Burgess, Jeremy D. , Siuda, Joanna S. , Morgan, Kevin , Price, Nathan D. , White, Charles, Soni, Rajesh K , Crook, Julia E. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_5 | Pages: No page available

10.1016/j.jalz.2016.06.451 Get It

P4‐031: Integrative Network Analysis of Multiple Alzheimer's Disease Rnaseq Studies From the Accelerating Medicine Partnership‐Alzheimer's Disease Consortium
Zhang, Bin , Komashko, Vitalina, Mostafavi, Sara , Funk, Cory C. , Allen, Mariet , Amberkar, Sandeep , Hide, Winston, Schadt, Eric , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Logsdon, Ben , Chen, Mingming , Perumal, Thanneer Malai , Hide, Winston, Friend, Stephen , Bennett, David A. , Price, Nathan D. , Mangravite, Lara M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2120 Get It

O1‐13‐03: The Mild Behavioral Impairment Checklist (MBI‐C): a New Rating Scale for Neuropsychiatric Symptoms as Early Manifestations of Neurodegenerative Disease
Ismail, Zahinoor , Cieślak, Alicja , Gauthier, Serge , Herrmann, Nathan , Kanji, Jamila, Mortby, Moyra E. , Onyike, Chiadikaobi, Ortiz, Luis Agüera, Rosenberg, Paul B. , Smith, Gwenn S. , Sultzer, David L. , Brodaty, Henry , Fischer, Corinne Eleanor , Geda, Yonas E. , Lanctôt, Krista L. , Miller, David, Onyike, Chiadi , Smith, Eric Edward , Cummings, Jeffrey L. , Lyketsos, Constantine G.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_4 | Pages: No page available

10.1016/j.jalz.2016.06.366 Get It

P4‐027: Combing Evidence Across Multiple Cohorts for Systems‐Based Target Discovery: the AMP‐AD Knowledge Portal
Allen, Mariet , Funk, Corey, Xu, Jishu , Logsdon, Ben , Yu, Lei , Schuyler, Sarah, Friend, Stephen , Schadt, Eric , Jager, Philip L. De , Ertekin‐Taner, Nilüfer , Dang, Kristen K. , Perumal, Thanneer Malai , Wang, Minghui , Bennett, David A. , Zhang, Bin , Price, Nathan D. , Mangravite, Lara M.

Mayo Clinic

Alzheimer's & Dementia | October 17, 2016 | Volume: 12 | Issue: 7S_Part_21 | Pages: No page available

10.1016/j.jalz.2016.06.2116 Get It

Casp8p41: The Protean Mediator of Death in CD4 T-cells that Replicate HIV
Sampath, Rahul , Badley, Andrew D. , Cummins, Nathan W. , Badley, Andrew D

Mayo Clinic

Journal of Cell Death | September 27, 2016 | Volume: 9 | Issue: No issue available | Pages: JCD.S39872

10.4137/jcd.s39872 | PMID 27721655 Get It

HIV cure is now the focus of intense research after Timothy Ray Brown (the Berlin patient) set the precedent of being the first and only person cured. A major barrier to achieving this goal on a meaningful scale is an elimination of the latent reservoir, which is thought to comprise CD4-positive cells that harbor integrated, replication-competent HIV provirus. These cells do not express viral proteins, are indistinguishable from uninfected CD4 cells, and are thought to be responsible for HIV viral rebound–-that occurs within weeks of combination anti retroviral therapy (cART) interruption. Modalities to engineer transcriptional stimulation (reactivation) of this dormant integrated HIV provirus, leading to expression of cytotoxic viral proteins, are thought to be a specific way to eradicate the latently infected CD4 pool and are becoming increasingly relevant in the era of HIV cure. HIV protease is one such protein produced after HIV reactivation that cleaves procaspase-8 to generate a novel protein Casp8p41. Casp8p41 then binds to the BH3 domain of BAK, leading to BAK oligomerization, mitochondrial depolarization, and apoptosis. In central memory T cells (TCMs) from HIV-infected patients, an elevated Bcl-2/procaspase-8 ratio was observed, and Casp8p41 binding to Bcl-2 was associated with a lack of reactivation-induced cell death. This was reversed by priming cells with a specific Bcl-2 antagonist prior to reactivation, resulting in increased cell death and decreased HIV DNA in a Casp8p41-dependent pathway. This review describes the biology, clinical relevance, and implications of Casp8p41 for a potential cure.
Team Cognition As a Means to Improve Care Delivery in Critically Ill Patients With Cancer After Hematopoietic Cell Transplantation
McNeese, Nathan J. , Khera, Nandita , Wordingham, Sara E., Arring, Noël , Nyquist, Sharon, Gentry, A.E., Sen, Ayan , Gentry, Amy, Tomlinson, Brian, Cooke, Nancy J, Tomlinson, Brian , Cooke, Nancy J.

Mayo Clinic

Journal of Oncology Practice | September 21, 2016 | Volume: 12 | Issue: 11 | Pages: 1091-1099

10.1200/jop.2016.013672 | PMID 27650839 Get It

Hematopoietic cell transplantation (HCT) is an important and complex treatment modality for a variety of hematologic malignancies and some solid tumors. Although outcomes of patients who have undergone HCT and require care in intensive care units (ICUs) have improved over time, mortality rates remain high and there are significant associated costs. Lack of a team-based approach to care, especially during critical illness, is detrimental to patient autonomy and satisfaction, and to team morale, ultimately leading to poor quality of care. In this manuscript, we describe the case of a patient who had undergone HCT and was in the ICU setting, where inconsistent team interaction among the various stakeholders delivering care resulted in a lack of shared goals and poor outcomes. Team cognition is cognitive processing at the team level through interactions among team members and is reflected in dynamic communication and coordination behaviors. Although the patient received multidisciplinary care as needed in a medically complicated case, a lack of team cognition and, particularly, inconsistent communication among the dynamic teams caring for the patient, led to mixed messages being delivered with high-cost implications for the health-care system and the family. This article highlights concepts and recommendations that begin a necessary in-depth assessment of implications for clinical care and initiate a research agenda that examines the effects of team cognition on HCT teams, and, more generally, critical care of the patient with cancer.